---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References"
description: "Reference list for the formulary evidence report on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea. 183 cited documents."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References

<a id="references"></a>

## 5 References

1. [Acquavella et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446073/)
2. [Aetna Zepbound prior authorization policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Zepbound%20PA%20with%20Limit%206192-C%2008-2026%20v3.html)
3. [Aishah et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8424567/)
4. [Aishah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36538809/)
5. [Ali et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13419131/)
6. [American Academy of Sleep Medicine Zepbound provider fact sheet (2026)](https://aasm.org/wp-content/uploads/2026/04/ProviderFS_Zepbound_2026-DIGITAL-2.pdf)
7. [Annemans et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42021523/)
8. [Apnimed CHEST 2025 release (2025)](https://apnimed.com/article/apnimed-to-present-additional-phase-3-data-for-ad109-an-investigational-oral-pill-for-obstructive-sleep-apnea-at-chest-2025-annual-meeting/)
9. [Apnimed debt financing release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-secures-150-million-debt-financing-healthcare-royalty)
10. [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)
11. [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)
12. [Apnimed LunAIRo statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/SAP_001.pdf)
13. [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/)
14. [Apnimed NDA acceptance release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-fda-acceptance-new-drug-application-ad109)
15. [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)
16. [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)
17. [Apnimed SASS monetization release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-strategic-monetization-shionogi-apnimed-sleep)
18. [Apnimed SynAIRgy protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/Prot_000.pdf)
19. [Apnimed SynAIRgy publication release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-publication-its-phase-3-synairgy-trial-ad109)
20. [Apnimed SynAIRgy statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/SAP_001.pdf)
21. [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/)
22. [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)
23. [Axsome Sunosi prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211230s009lbl.pdf)
24. [Ayas et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16682570/)
25. [Azarbarzin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6451769/)
26. [Azarbarzin et al. (2026)](https://academic.oup.com/ajrccm/article/doi/10.1093/ajrccm/aamag162.6399/8686692)
27. [Bailey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713924/)
28. [Baillieul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43033026/)
29. [Bailly et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039934/)
30. [Baldwin et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11204058/)
31. [Barbé et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22618923/)
32. [Benjafield et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7007763/)
33. [Berry et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3459210/)
34. [Bierer (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713911/)
35. [Boers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12674968/)
36. [Borsoi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9122203/)
37. [Cadby et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25927872/)
38. [Chervin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10075617/)
39. [Cistulli et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6589354/)
40. [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)
41. [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)
42. [ClinicalTrials.gov NCT04631107](https://clinicaltrials.gov/study/NCT04631107)
43. [ClinicalTrials.gov NCT04631107 results](https://clinicaltrials.gov/study/NCT04631107?tab=results)
44. [ClinicalTrials.gov NCT05071612](https://clinicaltrials.gov/study/NCT05071612)
45. [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)
46. [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)
47. [ClinicalTrials.gov NCT05811247 API record](https://clinicaltrials.gov/api/v2/studies/NCT05811247)
48. [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)
49. [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275)
50. [ClinicalTrials.gov NCT05813275 API record](https://clinicaltrials.gov/api/v2/studies/NCT05813275)
51. [ClinicalTrials.gov NCT05813275 results](https://clinicaltrials.gov/study/NCT05813275?tab=results)
52. [ClinicalTrials.gov NCT05813275 version 22](https://clinicaltrials.gov/study/NCT05813275?tab=history&a=22)
53. [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)
54. [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)
55. [CMS Medicare GLP-1 Bridge FAQs (2026)](https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf)
56. [CMS National Coverage Determination 240.4 (2008)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226)
57. [CMS National Coverage Determination 240.4.1 (2009)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=330)
58. [CMS Quality Payment Program measure 277 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_277_MIPSCQM.pdf)
59. [CMS Quality Payment Program measure 279 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_279_MIPSCQM.pdf)
60. [Cole et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12720397/)
61. [Eckert (2018)](https://pubmed.ncbi.nlm.nih.gov/28110857/)
62. [Eckert et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3826282/)
63. [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)
64. [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)
65. [Esmaeili et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12051718/)
66. [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)
67. [Gell et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41932835/)
68. [Gell et al. (2026b)](https://academic.oup.com/ajrccm/article/doi/10.1093/ajrccm/aamag162.6398/8686957)
69. [Gottlieb et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/9927364/)
70. [Gottlieb et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3117288/)
71. [Grace et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23220910/)
72. [Hedner et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35202553/)
73. [Heinzer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4404207/)
74. [Hoog et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210105/)
75. [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)
76. [Hudgel et al. (2018)](https://academic.oup.com/ajrccm/article/198/6/e70/8498283)
77. [Hurst et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42600422/)
78. [ICER obesity final report (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)
79. [Incannex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1873875/000162828026063506/ixhl-20260630.htm)
80. [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)
81. [Johns (1991)](https://pubmed.ncbi.nlm.nih.gov/1798888/)
82. [Kapur et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10505820/)
83. [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)
84. [Kaufmann et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13366499/)
85. [Kendzerska et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/23642349/)
86. [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/)
87. [Kim (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434379/)
88. [Kim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481018/)
89. [Kinouchi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36184258/)
90. [Kuna et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21471093/)
91. [Leng et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710301/)
92. [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)
93. [Lloyd et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9622990/)
94. [Luyster et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337594/)
95. [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)
96. [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)
97. [Marin et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15781100/)
98. [Marshall et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2542953/)
99. [Mazzotti et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6701040/)
100. [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599)
101. [McSharry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3920322/)
102. [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)
103. [Mehra et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2662909/)
104. [Messineo et al. (2023)](https://publications.ersnet.org/lookup/doi/10.1183/13993003.congress-2023.PA3594)
105. [National Sleep Foundation (2025)](https://www.thensf.org/wp-content/uploads/2025/03/NSF-Inpsire-Report_2025-1.pdf)
106. [Newman et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16287771/)
107. [Nieto et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10770144/)
108. [Nyxoah Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1857190/000110465926035161/nyxh-20251231x20f.htm)
109. [Ojile et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42247851/)
110. [Osman et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721662/)
111. [Parish and Lyng (2003)](https://pubmed.ncbi.nlm.nih.gov/12970021/)
112. [Patel et al. (2024)](https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A4551)
113. [Patel et al. (2025a)](https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A6932)
114. [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)
115. [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)
116. [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)
117. [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)
118. [Peker et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26914592/)
119. [Pépin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7957656/)
120. [Peppard et al. (2000a)](https://pubmed.ncbi.nlm.nih.gov/10805822/)
121. [Peppard et al. (2000b)](https://pubmed.ncbi.nlm.nih.gov/11122588/)
122. [Peppard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3639722/)
123. [Pietzsch et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3098944/)
124. [Pietzsch et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4402668/)
125. [Prado et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41915565/)
126. [Punjabi et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2722083/)
127. [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/)
128. [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/)
129. [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)
130. [Randerath et al. (2025)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01196-1/fulltext)
131. [Redline et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14572123/)
132. [Redline et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2913239/)
133. [Rehman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41735061/)
134. [Reichmuth et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2718458/)
135. [Rogers et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27792352/)
136. [Rosen et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3353048/)
137. [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)
138. [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/)
139. [Ruehland et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2635578/)
140. [Sajith Kumar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39773265/)
141. [Sánchez-de-la-Torre et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31839558/)
142. [Sánchez-de-la-Torre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10548300/)
143. [Sands et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019932/)
144. [Schweitzer et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9098382/)
145. [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)
146. [Senaratna et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27568340/)
147. [Sert Kuniyoshi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13056527/)
148. [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/)
149. [Srijithesh et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6491901/)
150. [Stepnowsky et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374092/)
151. [Stewart et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41089051/)
152. [Streatfeild et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31403163/)
153. [Strollo et al. (2014)](https://www.nejm.org/doi/full/10.1056/NEJMoa1308659)
154. [Strollo et al. (2024)](https://academic.oup.com/sleep/article/47/Supplement_1/A233/7654816)
155. [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)
156. [Strollo et al. (2025b)](https://academic.oup.com/sleep/article/48/Supplement_1/A339/8134797)
157. [Strollo et al. (2025c)](https://journal.chestnet.org/article/S0012-3692%2825%2905441-8/fulltext)
158. [Strollo et al. (2026a)](https://academic.oup.com/sleep/article/49/Supplement_1/A261/8673726)
159. [Strollo et al. (2026b)](https://academic.oup.com/sleep/article/49/Supplement_1/A302/8674486)
160. [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)
161. [Taranto-Montemurro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6519859/)
162. [Taranto-Montemurro et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7268440/)
163. [Taranto-Montemurro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12713960/)
164. [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)
165. [Teva Nuvigil prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf)
166. [Tishler et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12734134/)
167. [Tregear et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792976/)
168. [Tregear et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2941424/)
169. [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)
170. [Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22988888/)
171. [Weaver and Grunstein (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2645251/)
172. [Wellman et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3119134/)
173. [Wickwire et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7053009/)
174. [Wickwire et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8807906/)
175. [Woodson et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29582703/)
176. [Yaffe et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3600944/)
177. [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)
178. [Yeghiazarians et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34148375/)
179. [Young et al. (1993)](https://pubmed.ncbi.nlm.nih.gov/8464434/)
180. [Young et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9406321/)
181. [Young et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2542952/)
182. [Yu et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5541330/)
183. [Zhao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42269187/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
